Menu

Boosting Immunotherapy Treatments in Mouse Colon Cancer

Mice treated with an immunostimulant had better outcomes when researchers blocked the expression of TNFR2, a compound that helps tumors evade immune attack.

Apr 1, 2018
Jim Daley

GETTING DEFENSIVE: Tumors (cyan) create a cozy microenvironment to protect themselves from the immune system. Joseph Szulczewski, David Inman, Kevin Eliceiri, and Patricia Keely, Carbone Cancer Center at the Univ. of Wisconsin, National Cancer Institute, National Institutes of Health

EDITOR'S CHOICE IN CANCER IMMUNOTHERAPY

THE PAPER
Y. Nie et al., “Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer,” Sci Signaling, 11:eaan0790, 2018.

DEFENSIVE PARAMETER
Cancers are notorious for creating a no-fly zone around themselves—called the immunosuppressive tumor microenvironment—that is hostile to immunotherapy treatments. Determining ways to turn off immunosuppressive actors such as tumor-infiltrating regulatory T cells (Tregs) is vital to making immunotherapies more effective.

FRIEND OR FOE?
Conventional wisdom has long held that tumor necrosis factor (TNF) receptor type II (TNFR2) downregulates Treg function, says Xin Chen, a cancer researcher at the University of Macau. But his group had found that TNFR2 in fact acts with TNF to activate, expand, and stabilize the most immunosuppressive type of Tregs, and that it tends to be highly expressed in invasive and metastatic lung cancers. In a new study, Chen and colleagues blocked TNFR2 on Tregs.

THE BLOCKADE
Chen and his colleagues then treated mice that had mouse colon tumor cells grafted under their skin with a TNFR2-blocking antibody called M861 and a low dose of CpG oligodeoxynucleotides (ODN), an anticancer drug. Compared with mice given just CpG ODN, those treated with both drugs had fewer Treg cells, a greater immune response to the tumor, and longer tumor-free survival.

DOUBLING UP
“[The researchers] show the immense value of inhibiting TNFR2 for getting better survival of murine tumors,” says Denise Faustman, an immunobiology researcher at Massachusetts General Hospital. The study suggests, she says, that combining an immunostimulant with a drug that targets tumor-infiltrating Tregs “in effect, results in permanent tumor immunity.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Preparing Cell Or Tissue Lysates For ELISA Kits

Preparing Cell Or Tissue Lysates For ELISA Kits

RayBiotech manufactures over 2,000 high fully validated, GMP-compliant ELISA kits. In this blog post we explain how to prepare cell or tissue lysates for ELISA Kits.

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.